InsidersTradesSigma
Arrowhead Pharmaceuticals, INC. Stock: price and directors' dealings · United States · SEC (Form 4)
Track the Arrowhead Pharmaceuticals, INC. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Arrowhead Pharmaceuticals, INC. has logged 210 reports. Market capitalisation: €11.8bn. The latest transaction was disclosed on 17 June 2026 (Attribution). Among the most active insiders: Anzalone Christopher Richard. The full history is free.
210
Insider Decl.
0
Thresholds
€25,261
1 ops.
Buy Volume
€56m
136 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Arrowhead Pharmaceuticals, INC. Buy (bullish), based on 12 analysts. Average price target: US$89.08.
44Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 19,743 of 25,484 companies
32.6
score / 100
Value39
Quality26
FCF yld1.3%
Earn yld-0.0%
EV/EBITDA·
ROE-42%
Gross mgn·
Net mgn-0.2%
Debt/EBITDA2.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 17 June 2026
Declarations210 total
11,882 sharesCommon StockSEC:0002141314-26-000004:0
10,000 shares@ US$75.000.0058% mcap15.6% of flowCommon StockSEC:0001830755-26-000007
10,000 shares@ US$75.000.0059% mcap15.6% of flowCommon StockSEC:0001830755-26-000007:0
3,208 shares@ US$70.110.0017% mcap50.0% of flowCommon StockSEC:0000879407-26-000039
3,208 shares@ US$70.110.0018% mcap50.0% of flowCommon StockSEC:0000879407-26-000039:0
7,416 shares@ US$65.880.0039% mcap3.4% of flowCommon StockSEC:0001423029-26-000001:0
4,625 shares@ US$61.240.0022% mcap5.9% of flowCommon StockSEC:0001830755-26-000002:0
560 shares0Common StockSEC:0001627183-26-000001:0
560 shares0Common StockSEC:0001627183-26-000001
7,416 shares@ US$65.883.4% of flowCommon StockSEC:0001423029-26-000001
4,625 shares@ US$61.245.9% of flowCommon StockSEC:0001830755-26-000002
35,181 shares@ US$6.151.5% of flowCommon StockSEC:0001423029-25-000009
35,181 shares@ US$6.150.0017% mcap1.5% of flowCommon StockSEC:0001423029-25-000009:0
16,545 shares@ US$6.150.3% of flowCommon StockSEC:0001423029-25-000009:1
35,181 shares@ US$69.336.3% of flowCommon StockSEC:0001423029-25-000009:2
16,545 shares@ US$68.692.9% of flowCommon StockSEC:0001423029-25-000009:3
7,530 shares@ US$70.0026.8% of flowCommon StockSEC:0001506045-25-000007:0
2,799 shares@ US$66.630.0015% mcap50.0% of flowCommon StockSEC:0001826263-25-000006:0
2,799 shares@ US$66.6350.0% of flowCommon StockSEC:0001826263-25-000006
3,979 shares@ US$66.671.8% of flowCommon StockSEC:0001423029-25-000007
3,090 shares@ US$66.7021.8% of flowCommon StockSEC:0001242615-25-000006
2,416 shares@ US$66.6626.8% of flowCommon StockSEC:0001553338-25-000005
3,979 shares@ US$66.670.0021% mcap1.8% of flowCommon StockSEC:0001423029-25-000007:0
25 of 210 declarations
About Arrowhead Pharmaceuticals, INC.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is a United States-based biopharmaceutical company focused on RNA interference (RNAi) therapeutics, a gene-silencing approach designed to shut down disease-causing proteins at the source. The company is headquartered in Pasadena, California, with major research and development operations in Madison, Wisconsin and San Diego, California, plus chemistry and manufacturing capabilities in Verona, Wisconsin. Founded in May 2003, Arrowhead has spent more than two decades building scientific capabilities around RNAi delivery and target selection, now centered on its proprietary TRiM™ platform. From an industry standpoint, Arrowhead sits in the specialized precision-medicine segment of healthcare, with a business model that combines platform innovation, internal pipeline development, and an emerging commercial footprint. Its strategy is to apply RNAi across multiple disease areas rather than rely on a single therapeutic niche. Management describes TRiM™ as tissue-agnostic, enabling the company to pursue cardiometabolic, liver, pulmonary, neurological and other hard-to-treat conditions. That breadth is a competitive strength because it creates multiple shots on goal, although the company still faces the usual biotech challenges of clinical execution, regulatory approval and commercialization. A major recent milestone is the FDA approval of REDEMPLO® (plozasiran) in November 2025 for adults with familial chylomicronemia syndrome (FCS), a rare and severe disorder characterized by extremely elevated triglycerides and a high risk of pancreatitis. In December 2025, plozasiran also received FDA Breakthrough Therapy designation in severe hypertriglyceridemia, and in 2026 Arrowhead announced a positive CHMP opinion in Europe. These developments are important because they validate the platform clinically and move Arrowhead from a pure development story toward a company with its first marketed asset and the possibility of broader international expansion. Beyond plozasiran, Arrowhead continues to advance a pipeline of RNAi candidates in obesity and other cardiometabolic indications, as well as programs that explore newer delivery systems and potential central nervous system applications. The company’s competitive position is therefore based less on scale than on scientific differentiation, delivery technology and the ability to convert platform assets into approvable medicines. For investors in French-speaking markets, Arrowhead represents a high-upside, high-risk U.S. NASDAQ-listed biotech with meaningful pipeline optionality, a first commercial product, and a clear focus on gene-silencing therapeutics.
